The presence of obesity-related metabolic disturbances varies widely among obese individuals. Accordingly, a unique subset of obese individuals has been described in the medical literature, which seems to be protected or more resistant to the development of metabolic abnormalities associated with obesity. These individuals, now known as 'metabolically healthy but obese' (MHO), despite having excessive body fatness, display a favorable metabolic profile characterized by high levels of insulin sensitivity, no hypertension as well as a favorable lipid, inflammation, hormonal, liver enzyme and immune profile. However, recent studies have indicated that this healthier metabolic profile may not translate into a lower risk for mortality. Mechanisms that could explain the favorable metabolic profile of MHO individuals are poorly understood. However, preliminary evidence suggests that differences in visceral fat accumulation, birth weight, adipose cell size and gene expression-encoding markers of adipose cell differentiation may favor the development of the MHO phenotype. Despite the uncertainty regarding the exact degree of protection related to the MHO status, identification of underlying factors and mechanisms associated with this phenotype will eventually be invaluable in helping us understand factors that predispose, delay or protect obese individuals from metabolic disturbances. Collectively, a greater understanding of the MHO individual has important implications for therapeutic decision making, the characterization of subjects in research protocols and medical education. Keywords: metabolically healthy but obese; insulin sensitivity; body composition; metabolic risk factors; cardiovascular diseases Introduction Obesity has been increasing at a rapid rate over the past decades and has now reached epidemic proportions. Recent data suggest that 65% of US adult are overweight (body mass index425 kg m
Introduction
Obesity has been increasing at a rapid rate over the past decades and has now reached epidemic proportions. Recent data suggest that 65% of US adult are overweight (body mass index425 kg m
À2
) and 30% are obese (body mass index430 kg m
). 1 Obesity is associated with numerous metabolic complications such as Type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases and several forms of cancer. 2 The risk of developing obesity-related complications is proportional to the degree of obesity, and more specifically to android fat accumulation. 3 However, the presence of these obesity-related metabolic disturbances varies widely among obese individuals. 4, 5 Accordingly, a unique subset of obese individuals has been described in the medical literature that seems to be protected or more resistant to the development of metabolic abnormalities associated with obesity. [6] [7] [8] [9] [10] [11] [12] These individuals, now known as 'metabolically healthy but obese' (MHO), despite having excessive body fatness, display favorable metabolic profiles characterized by high levels of insulin sensitivity, no hypertension, as well as favorable lipid, inflammation, hormonal, liver enzyme and immune profiles 7, 9, [13] [14] [15] ( Figure 1 ). This phenomenon has also been observed in adolescents. 16 Despite a clinical awareness of the MHO individual, factors or mechanisms underlying this protective profile are not known. Therefore, the purpose of this review was to provide an overview of the characteristics and potential mechanisms underlying the 'protective profile' of this unique subset of obese individuals. A PubMed database search was performed using the following keywords: metabolically healthy obese, metabolically normal obese, insulin sensitive obese and uncomplicated obesity.
Evidence of a subgroup of metabolically healthy but obese individuals (MHO)
The concept of the MHO individual was first described in the 1980s 17, 18 and epidemiological evidence suggests that these individuals may account for as much as 30% of the obese population. 4, 5, 19 Although the existence of this subtype of obesity is now well recognized, there remains the difficulty to adequately standardize the identification of MHO individuals. The common underlying principal criterion used to identify MHO individuals is the absence of metabolic complications (that is, inflammation, dyslipidemia and hypertension) and/or preserved insulin sensitivity despite excessive body fatness. Several studies have identified MHO individuals based on insulin sensitivity using the gold-standard hyperinsulinemic-euglycemic clamp technique. 7, 9, 20 However, this technique is invasive, expensive as well as time consuming. Therefore, other methods based on insulin sensitivity have been used to identify MHO individuals, such as the Matsuda index, 15 (Table 1) . Prevalence of MHO individuals highly depends on the definition used. Indeed, epidemiological and clinical studies suggest that the prevalence of MHO subjects may vary between 10 and 40% ( Table 1) . The two largest studies using samples representative of the general population have reported prevalence between 30 and 40% of the obese population. 11, 19 Moreover, factors such as ethnic background, age and physical activity level affect reported MHO prevalence. Wildman et al. 19 showed that the prevalence of MHO individuals is higher in non-Hispanic white population. Cross-sectional epidemiological studies also suggest that MHO prevalence is higher in younger individuals ( Figure 2 ) and slightly higher in women. 24, 25 Finally, it should be noted that several studies have defined MHO individuals based on the extremes of insulin sensitivity (that is, upper quartiles or lower tertiles). 11, 15, 20, 26, 27 Therefore, caution should be taken with the prevalence of MHO subjects (that is, 25 or 33%) in these studies because the number is simply a reflection of the predefined selection criteria. In addition, several studies have reported that lean body mass (LBM) was significantly lower in MHO individuals compared with MAO subjects. 7, 9, 20 For example, our group has previously shown that the combination of high LBM and high visceral adipose tissue was associated with further deterioration in the metabolic profile compared with the combination of high visceral adipose tissue and normal LBM. 34 Whether increased LBM is a consequence of metabolic disturbances or whether it has a causal function in the development of the MAO phenotype remains to be investigated. Interestingly, a recent study showed that muscle strength was significantly higher in MHO individuals despite lower levels of LBM. 35 Further studies are needed to investigate the role of LBM and the production of muscle force in obesityrelated metabolic disturbances in the MHO phenotype.
Body composition and body fat distribution

Clinical and biochemical characteristics of MHO individuals
As most studies on MHO individuals have used insulin sensitivity to identify this subset of obese individuals, it is not surprising that significant differences in insulin sensitivity are observed between MHO and MAO individuals. 7, 9, 11, 15, 20, 36 In most studies, higher insulin sensitivity in MHO subjects was accompanied with lower fasting glucose 7, 15, 20 and insulin levels. 7, 9, 13, 15, 20, 36 In addition, Marini et al. 20 reported that 2-h post-challenge plasma glucose level was lower in MHO individuals, whereas Stefan et al. 15 showed that insulin clearance was higher in MHO subjects compared with MAO individuals. Moreover, a recent study reported that glycosylated hemoglobin level was significantly lower in MHO individuals. 14 Several studies have also shown that MHO individuals present a favorable blood lipid profile as evidenced by lower triglycerides (TGs) and higher high density lipoprotein (HDL) cholesterol levels, and favorable hepatic enzyme profile as evidence by lower aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) levels compared with MAO subjects. 7, 9, 13, 20, 22, 36 Other clinical characteristics include lower oxidized low density lipoprotein 22 and free-fatty acid 15, 36 concentrations in MHO subjects. Results on blood pressure in MHO individuals are less consistent than those observed for blood lipids. Accordingly, several studies observed lower blood pressure in MHO individuals, 20, 26, 36 whereas others have not. 7, 9 Finally, recent data indicates that the favorable metabolic profile of MHO subjects extends to the immune system with higher circulating levels of natural killer cells and cytotoxic T lymphocytes. 14 
Hormonal and inflammation profiles of MHO individuals
Once considered a passive energy reservoir, adipose tissue is now recognized as an important endocrine organ that secretes a variety of hormones or adipokines involved in metabolism. Obesity, insulin resistance and diabetes are associated with lower adiponectin levels. Several studies have reported higher levels of adiponectin in MHO than in MAO individuals. 13, 16, 26, 37, 38 In addition, a recent study extended these results by showing that MHO individuals had significantly higher levels of high-molecular weight adiponectin compared with MAO individuals. 39 However, the ability of acute hyperinsulinemia to reduce plasma adiponectin levels is not different between MHO and MAO. 39 Whether adiponectin levels have a function in the MHO phenotype is unknown. It has been suggested that adiponectin may have an effect on lipid partitioning. 40 Interestingly, in ob/ob mice, a model of extreme obesity and insulin resistance, overexpression of full-length adiponectin promotes subcutaneous adipose tissue expansion primarily through adipose tissue hyperplasia, resulting in improved insulin sensitivity. 41 This observation could explain, in part, the lower visceral fat content in MHO individuals. In addition, the presence of adiponectin-specific receptors in the muscle, liver and pancreas suggest that this hormone may have a function in mediating substrate use. 42, 43 Indeed, adiponectin has been shown to be negatively associated with fasting carbohydrate oxidation rates. The metabolically healthy but obese subject V Primeau et al postmenopausal women. Ghrelin is a stomach-derived peptide involved in the regulation of growth hormone secretion, 44 food intake 45 and energy metabolism. 46, 47 Two distinct forms of ghrelin are found in circulation: acylated and nonacylated. Orexigenic and diabetogenic effects are associated with acylated ghrelin, whereas the nonacylated form could have antidiabetogenic functions. St-Pierre et al. 38 observed that MHO individuals displayed a significantly lower fasting ratio of acylated/nonacylated ghrelin compared with MAO subjects. During a hyperinsulinemiceuglycemic clamp, reductions in total ghrelin concentrations were observed in both MHO and MAO women. However, the decrease of total ghrelin concentrations was significantly greater in MHO subjects than in MAO individuals. In contrast to total ghrelin levels, acylated ghrelin concentrations were only significantly reduced in MHO subjects, whereas these levels increased slightly in MAO subjects under hyperinsulinemia. These results suggest that MHO overweight and obese individuals display an increased and sustained capacity to reduce total and acylated ghrelin levels under hyperinsulinemia. Furthermore, Marini et al. 20 reported that insulin-like growth factor-1 (IGF-1) levels were lower in MHO and MAO subjects compared to nonobese individuals. However, there was no difference in IGF-1 levels between MHO and MAO subjects. Plasma IGF-1 levels were observed to be associated with carotid intima-media thickness, suggesting that low IGF-1 levels could contribute to early atherosclerosis in obese individuals. 20 Moreover, low-tissue IGF-1 levels and reduced IGF-1 receptor expression have been found in atherosclerotic plaques. 48 Finally, it has been reported that the MHO status is associated with a significantly lower sub-clinical inflammation profile. 9, 22 For example, Karelis et al. 9 showed that high-sensitivity C-reactive protein and alpha-1 antitrypsin levels were significantly lower in MHO individuals. In addition, level of interleukin-6, the major cytokine stimulating hepatic C-reactive protein production, has also been reported to be lower in MHO subjects. 22 On the basis of these results and on the predictive value of a higher high-sensitivity C-reactive protein for future cardiovascular risk, 49 it has been proposed that a low high-sensitivity C-reactive protein level be included in the definition of the MHO phenotype. 21 It is important to note that in all studies related to hormonal and inflammatory differences, despite significant mean differences, a major overlap exists between values observed in MHO and MAO subject, thus no clear cutoff values could be suggested.
Energy intake, expenditure and cardiorespiratory function
Despite significant differences in body composition and in the metabolic profile, few studies have reported differences in energy expenditure and cardiorespiratory function between MHO and MAO individuals. 7, 9, 16, 22 Only two studies have shown that physical activity energy expenditure was higher in MHO individuals compared to MAO individuals. 19, 29 Furthermore, Shin et al. 22 have reported that energy intake and diet composition were not different between MHO and MAO subjects.
Psychosocial profile
Previous studies have reported that psychosocial factors were associated with metabolic abnormalities. It could thus be hypothesized that MHO individuals would present a favorable psychosocial profile compared with MAO subjects.
To the best of our knowledge, only one study has investigated psychosocial factors in MHO individuals and showed that there were no significant differences for quality of life, perceived stress, self-esteem, body esteem, perceived benefits, self-efficacy and perceived risks for heart disease and diabetes between MHO and MAO individuals. 50 
Predisposition to the MHO phenotype
It is possible that some factors may predispose individuals to the MHO phenotype. Accordingly, it has been shown that high birth weight and early weight gain were associated with higher whole-body insulin sensitivity and lower hepatic insulin resistance, suggesting that these factors may contribute to the MHO phenotype. 51 Similarly, Brochu et al.
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reported that early onset of obesity was associated with a more favorable metabolic profile in MHO women. That is, a tendency for a greater percentage of MHO women became obese during adolescence compared to MAO (48 vs 29%, respectively; P ¼ 0.09). 7 The mechanisms that could explain the relationship between the favorable metabolic profile in MHO and early onset of obesity are not well known. It is possible that high insulin sensitivity levels in MHO may have been a metabolic factor contributing to earlier onset of obesity. In accordance, it has been observed that high levels of insulin sensitivity are predictive of future weight gain. 52 Furthermore, there is a possibility that an underlying insulin-resistance state may have buffered weight gain, leading to a later onset of obesity in MAO individuals. 53, 54 Finally, no differences in familial medical history (that is, frequency of parents with diabetes and cardiovascular disease) have been reported in MHO subjects compared to MAO individuals. 55 However, this study was done with a small number of subjects and further studies with larger sample size are needed to confirm this finding.
Effect of weight loss in MHO individuals
Several studies have shown that weight loss improves insulin sensitivity and metabolic abnormalities and reduces the risk heavier subjects exposed to a more pronounced weight loss. Moreover, a recent study explored the impact of a physical activity program and here again no metabolic benefit was observed. 60 Furthermore, Karelis et al. 61 investigated the effect of a 6-month energy-restricted diet on insulin sensitivity using the hyperinsulinemic-euglycemic clamp technique in a sample of MHO postmenopausal women. No significant difference was observed for weight loss between MHO and MAO subjects. By design, insulin sensitivity was higher in MHO individuals and this difference persisted after the 6-month diet. By the end of the diet, insulin sensitivity levels had significantly increased by 26.1% in MAO subjects and had significantly decreased by 12.8% in MHO women (Figure 3) , suggesting that MHO individuals may respond differently to an energy-restricted diet compared to MAO individuals who achieve a similar weight loss. Future studies should confirm this intriguing finding and may want to examine the impact of other lifestyle modification, such as exercise training on the metabolic profile of MHO individuals. However, it should be noted that despite the absence of improvement or even the presence of deterioration in the metabolic profile of MHO subjects after a weight loss intervention, MHO individuals always presented a more favorable metabolic profile than the improved metabolic profile observed in MAO subjects. and obese individuals with or without insulin resistance for 7-11 years. They showed that obese individuals with the metabolic syndrome or insulin resistance (MAO) were at increased risk of diabetes and cardiovascular diseases compared to obese subjects without the metabolic syndrome or insulin resistance (MHO) (Figure 4 ). Moreover, Meigs et al. 11 reported that MHO subjects, regardless of body mass index category, were not at increased risk for cardiovascular diseases compared to normal-weight subjects without Figure 4 The 7-year age-sex-adjusted cumulative incidence of Type 2 diabetes and 11-year adjusted cumulative incidence of cardiovascular diseases in metabolically healthy obese and metabolically abnormal individuals. Adapted from Meigs et al.
Future cardio-metabolic risk
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The metabolically healthy but obese subject V Primeau et al insulin resistance. 11 Similarly, St-Pierre et al. 65 followed a cohort of nondiabetic men free of ischemic heart disease with or without the insulin resistance syndrome for 13 years. This study showed that obese men with fewer than three features of the insulin-resistance syndrome were not at increased risk of ischemic heart disease. 65 However, two recent longitudinal studies have refuted the idea that obesity without metabolic complications is a benign condition. Accordingly, Arnlöv et al. 66 assessed cardiovascular risk factors and death in 1758 middle-aged men without diabetes during a follow-up of more than 30 years. This study observed that obese men without the metabolic syndrome, corresponding to the MHO phenotype, had an increased risk for cardiovascular events and death over 30 years compared to normal-weight individuals without the metabolic syndrome. In contrast to previous studies, the risk of cardiovascular disease and mortality was similar in MHO and MAO individuals. Furthermore, Kuk et al.
67
examined the risk for all-cause mortality in a sample of 6011 adults followed for approximately 10 years. In that study, insulin resistance or the metabolic syndrome criteria were used to identify MHO and MAO. Kuk et al. 67 reported that obese individuals were at higher risk of mortality than nonobese individuals regardless of whether they presented insulin resistance or a clustering of metabolic risk factors. Finally, it is important to note that the risk of mortality was similar in MHO and MAO individuals ( Figure 5 ). Taken together, these results suggest that despite a lower risk for Type 2 diabetes and possibly cardiovascular disease and the potential absence of improvement in the metabolic profile of MHO subjects after weight loss, lifestyle interventions (weight management and physical activity) should continue to be recommended to reduce total mortality in all obese individuals. 68 Furthermore, several studies have shown that gastric bypass surgery may reduce the risk of mortality in obese subjects. 69, 70 However, no data seem to be currently available on the effect of gastric bypass surgery in MHO individuals.
Clinical implication
One of the major challenges has been the difficulty to adequately standardize the identification of MHO individuals, which may render findings and/or conclusions difficult to interpret. To date, there is no standardized terminology or method to identify MHO individuals for research protocols or in clinical practice, except for the presence of an obese state (body mass indexX30 kg m
À2
). We recently compared the impact of different methods (three insulin sensitivity indices: hyperinsulinemic-euglycemic clamp, OGTT and HOMA and two methods based on several metabolic risk factors) used to identify MHO individuals on the MHO phenotype in a cohort of obese postmenopausal women. 71 Results of that study showed differences in body composition (that is, peripheral fat mass) and metabolic risk factors (that is, HDL-C) in MHO women when these subjects were compared to at risk women using five different methods to categorize subjects. It should also be noted that few metabolic differences were observed between 'metabolically healthy obesity' subjects identified using metabolic risk factors and 'insulin sensitive obesity' individuals identified using insulin sensitivity indices. However, we noted several recurrent characteristics in MHO subjects across the five methods used, such as lower plasma levels of TGs, ApoB, fasting insulin and ferritin and a lower TG/ HDL-C ratio and higher insulin sensitivity (HOMA Figure 5 Relative risk of all-cause mortality by metabolic status as defined by insulin resistance in normal weight and obese men and women. *Hazard ratio significantly different from metabolically normalFnormal weight individuals (Po0.05). No differences were observed between metabolically normal obese subjects and metabolically abnormal obese individuals. Adapted from Kuk and Ardern. 67 The metabolically healthy but obese subject V Primeau et al determination of HOMA and oral glucose tolerance test indices may also need to be re-evaluated. The absence of standardization for insulin assay does not allow proposing a strict definition for the HOMA index and oral glucose tolerance test indices which validity is limited to the specific radioimmunoassay used. Therefore, we believe that an expert consensus may be needed to standardize the identification of MHO individuals.
It is important to educate healthcare professionals, researchers and physicians regarding the different subtypes of obese individuals. A better understanding of MHO individuals has important implications for medical education and research. For example, the identification of the MHO individual in a clinical setting could have important implications for therapeutic medical decision-making, such as prioritizing various approaches to treat obese individuals. Furthermore, identifying factors and mechanisms of this protective phenotype would certainly improve the treatment of obese patients, to reduce the cardiometabolic risk. Moreover, it should be noted that MHO individuals are not 'without risk' because they still present a risk for mortality, as shown by two recent studies, 66, 67 and also because they may be exposed to other obesity-associated complications, such as osteoarthritis and obstructive sleep apnea. 
Future studies and potential mechanisms
As mentioned earlier, the mechanisms that could explain the favorable metabolic profile of MHO individuals are largely unknown. It has been previously suggested that adipose cell size could be a link between obesity and insulin resistance. Studies dating back to the 1970s showed that obese individuals with enlarged subcutaneous abdominal adipose cells were more likely to be hyperinsulinemic and glucoseintolerant than individuals with smaller adipose cells. [72] [73] [74] [75] These findings led to the idea that individuals with hypertrophic adipose cells were more likely to be insulinresistant and develop diabetes. 76 To our knowledge, only one study examined adipose cells size in MHO individuals. 77 In that study, McLaughlin et al. 77 compared adipose cells size between 15 MHO and 13 MAO individuals. In contradiction with the hypothesis, this study showed that MAO subjects had a higher proportion of small adipose cells compared to MHO individuals.
In addition, future studies may want to target free fatty acid storage and utilization in MHO individuals. In support of this idea, Gavrilova et al. 78 showed that transplantation of adipose tissue into a transgenic mouse, which has virtually no white adipose tissue, significantly reversed hyperglycemia, lowered insulin levels and improved muscle insulin sensitivity. Moreover, expression of gene markers reflecting adipose cell differentiation, such as peroxisome proliferator-activated receptor gamma and sterol receptor element-binding protein, were at least two-fold higher in MHO subjects. The same team recently provided additional evidence of the association between small adipocytes with inflammation and insulin resistance. 27 On the basis of these results, it was hypothesized that insulin resistance occurs in obese individuals because of their inability to respond to the need to store free fatty acids by increasing the production of fully differentiated and mature adipose cells. Remodeling of dysfunctional adipose tissue into a healthier tissue seems to be a promising new approach to treat obesity. Adipocyte remodeling has been observed in response to the peroxisome proliferator-activated receptor gamma agonist thiazolidinedione 79 and benzopyran-derived T33, 80 but also human adenovirus type 36. 81, 82 Animal studies have
shown that infection with this virus improved insulin sensitivity and reduced the expression of the inflammatory cytokine macrophage chemoattractant protein-1. Furthermore, infected tissues showed increased adipogenesis leading to the expansion of adipose tissue. 83, 84 Interestingly, in animals infection with the virus was associated with better glycemic control, suggesting that identification of the viral protein mediating this effect may have therapeutic promise. 85 Future studies should broaden our understanding regarding the role of gene expression in MHO subjects. In key tissues such as muscle, insulin regulates over 700 genes 86 and insulin resistance is associated with important changes in the expression level of key genes in many insulin-signaling pathways. 87 In addition, insulin sensitivity modulates the ability of insulin to stimulate or repress the expression of key genes associated with insulin resistance and inflammation. 88 Furthermore, whether polymorphisms of key genes modulate the appearance of the MHO phenotype remains to be demonstrated. Collectively, such investigations could potentially broaden our understanding regarding the pathophysiology of the protective metabolic characteristics of the MHO individual, which may lead to a better understanding of the mechanisms of insulin resistance and/or insulin secretion and in turn contribute to the understanding of the factors involved in the etiology of Type 2 diabetes and cardiovascular disease.
